<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943744</url>
  </required_header>
  <id_info>
    <org_study_id>58997</org_study_id>
    <nct_id>NCT04943744</nct_id>
  </id_info>
  <brief_title>Gastrointestinal STRING Test With Oral Immunotherapy</brief_title>
  <acronym>STRING</acronym>
  <official_title>Monitoring Gastrointestinal Responses In Food Oral Immunotherapy Using the Esophageal STRING Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This STRING study will examine markers of esophageal inflammation using a minimally-invasive&#xD;
      testing device, the esophageal string test (EST). The primary objective is to determine the&#xD;
      effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic&#xD;
      inflammation in the esophagus of subjects treated with omalizumab-facilitated&#xD;
      mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a companion study to a phase 2 randomized, controlled, double-blind clinical trial&#xD;
      using biologics to improve multi-allergen oral immunotherapy (mOIT) outcomes. The parent&#xD;
      study (COMBINE NCT03679676) consists of a screening period, 8 weeks of omalizumab or placebo&#xD;
      injections, and 24 weeks of OIT with dupilumab or placebo injections followed by an&#xD;
      off-treatment period.&#xD;
&#xD;
      This STRING companion study will examine markers of esophageal inflammation during the&#xD;
      COMBINE study using a minimally-invasive testing device, the esophageal string test (EST). If&#xD;
      participants of COMBINE consent to this companion study, they will undergo an esophageal&#xD;
      string test at the following time points in COMBINE:&#xD;
&#xD;
        -  During screening, prior to week 0, which will be baseline for the STRING esophageal test&#xD;
&#xD;
        -  Week 8, After the 8 weeks of treatment with omalizumab/placebo&#xD;
&#xD;
        -  If dose-related gastrointestinal (GI) side effects occur during the week 10-32 treatment&#xD;
           period (OIT and dupilumab/placebo)&#xD;
&#xD;
        -  At Week 32, after 24 weeks of treatment with OIT and dupilumab or placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the proportion of subjects with esophageal eosinophilia (EE)</measure>
    <time_frame>32 weeks</time_frame>
    <description>(defined as an EST score ≥ 2.9) in subjects receiving omalizumab-facilitated mOIT and/or mOIT with concurrent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of EST scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>Comparison of EST scores (composite measure of eosinophilic inflammation) before and after treatment with omalizumab</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Eosinophilic Disorder</condition>
  <condition>Food Allergy</condition>
  <arm_group>
    <arm_group_label>String Test</arm_group_label>
    <description>Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Entero-tracker</intervention_name>
    <description>Esophageal STRING test (Entero-tracker)</description>
    <arm_group_label>String Test</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cells and biofluids&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in the COMBINE study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: • Participants, aged 5-55 years enrolled in the parent COMBINE trial&#xD;
&#xD;
          -  Able to swallow the EST.&#xD;
&#xD;
        Exclusion Criteria: • Allergy to, or inability to ingest, gelatin&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Chinthrajah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sean N Parker Center for Allergy and Asthma Research at Stanford University</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>R. Sharon Chinthrajah</investigator_full_name>
    <investigator_title>Medical Director, Clinical Research Uni</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eosinophilia</mesh_term>
    <mesh_term>Food Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

